OBJECTIVE: Women with ovarian cancer face a poor prognosis, with prolonged periods of treatment but relatively high levels of physical functioning. Their thoughts and feelings regarding the prospect of dying are complex and have not been adequately studied. Various demographic, medical and psychosocial factors were examined to determine their independent associations with fear of dying and hopelessness in a cross-sectional design. METHOD: Two hundred fifty-four ovarian cancer patients were assessed at the beginning of a new chemotherapy regimen. Separate logistic regressions were performed for worry about dying and loss of hope. For each analysis, psychosocial variables were entered after the demographic and medical variables to determine whether the psychosocial variables had an independent association with the respective outcome. RESULTS: Fifty-five percent of the sample acknowledged fear of dying, and 31.6% acknowledged loss of hope in the fight against their illness. Being younger (p = .001), being of non-Hispanic White ethnicity (p = .026), and having poorer physical well-being (p = .000) were significantly associated with worry about dying after controlling for all other variables in the model. Regarding loss of hope, depressive symptoms (p = .002), lack of social support/well-being (p = .001), and number of treatments (p = .04) were significant. SIGNIFICANCE OF RESULTS: This is one of the largest studies to examine end-of-life concerns in a sample of advanced cancer patients. Our results underscore the importance of demographic and psychosocial variables in the examination of ovarian cancer patients' end-of-life concerns. Their fears and concerns should be openly acknowledged, even when the clinical focus is still on curative treatment.
OBJECTIVE:Women with ovarian cancer face a poor prognosis, with prolonged periods of treatment but relatively high levels of physical functioning. Their thoughts and feelings regarding the prospect of dying are complex and have not been adequately studied. Various demographic, medical and psychosocial factors were examined to determine their independent associations with fear of dying and hopelessness in a cross-sectional design. METHOD: Two hundred fifty-four ovarian cancerpatients were assessed at the beginning of a new chemotherapy regimen. Separate logistic regressions were performed for worry about dying and loss of hope. For each analysis, psychosocial variables were entered after the demographic and medical variables to determine whether the psychosocial variables had an independent association with the respective outcome. RESULTS: Fifty-five percent of the sample acknowledged fear of dying, and 31.6% acknowledged loss of hope in the fight against their illness. Being younger (p = .001), being of non-Hispanic White ethnicity (p = .026), and having poorer physical well-being (p = .000) were significantly associated with worry about dying after controlling for all other variables in the model. Regarding loss of hope, depressive symptoms (p = .002), lack of social support/well-being (p = .001), and number of treatments (p = .04) were significant. SIGNIFICANCE OF RESULTS: This is one of the largest studies to examine end-of-life concerns in a sample of advanced cancerpatients. Our results underscore the importance of demographic and psychosocial variables in the examination of ovarian cancerpatients' end-of-life concerns. Their fears and concerns should be openly acknowledged, even when the clinical focus is still on curative treatment.
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Colleen McClain-Jacobson; Barry Rosenfeld; Anne Kosinski; Hayley Pessin; James E Cimino; William Breitbart Journal: Gen Hosp Psychiatry Date: 2004 Nov-Dec Impact factor: 3.238
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart Journal: Thyroid Date: 2019-07-25 Impact factor: 6.568
Authors: Sharon L Manne; Shannon Myers-Virtue; David Kissane; Melissa L Ozga; Deborah A Kashy; Stephen C Rubin; Norman G Rosenblum; Carolyn J Heckman Journal: Psychooncology Date: 2016-08-09 Impact factor: 3.894
Authors: Shannon B Myers; Sharon L Manne; David W Kissane; Melissa Ozga; Deborah A Kashy; Stephen Rubin; Carolyn Heckman; Norman Rosenblum; Mark Morgan; John J Graff Journal: Gynecol Oncol Date: 2012-10-23 Impact factor: 5.482
Authors: Katrina F Trivers; Jennifer Rees Patterson; Katherine B Roland; Juan L Rodriguez Journal: Support Care Cancer Date: 2013-07-12 Impact factor: 3.603
Authors: Maria Papaleontiou; Mousumi Banerjee; Di Yang; James C Sisson; Ronald J Koenig; Megan R Haymart Journal: Thyroid Date: 2013-02 Impact factor: 6.568
Authors: Rachel A Rodenbach; Andrew D Althouse; Yael Schenker; Thomas J Smith; Edward Chu; Douglas B White; Marie Bakitas; Robert M Arnold Journal: J Pain Symptom Manage Date: 2020-09-12 Impact factor: 3.612